Corona Remedies IPO GMP Today: Listing Premium and Full Investment Review

The Indian pharmaceutical sector is set to witness one of its most anticipated listings as Corona Remedies Limited prepares to launch its ₹655.37 crore Mainboard IPO. Positioned as one of the fastest-growing pharmaceutical companies in the Indian Pharmaceutical Market (IPM), Corona Remedies offers investors a compelling combination of robust financial growth, low leverage, and a focused portfolio.

The IPO subscription window opens soon, running from December 8 to December 10, 2025. If you’re deciding whether to participate, understanding the current market sentiment, particularly the Corona Remedies IPO GMP, is essential. Let’s dive into a detailed, human-perspective review covering the valuation, financials, and listing potential.

Corona Remedies IPO GMP: What’s the Listing Hype Saying?

The Grey Market Premium (GMP) is the best real-time indicator of how the market expects an IPO to perform upon listing. The Corona Remedies IPO GMP has been showing exceptional strength, reflecting high confidence in the company’s strong financial trajectory.

As of today, December 5, 2025, the estimated premium is substantial:

What This Means for Investors:

A potential listing gain of over 30% is a fantastic cushion. This level of GMP indicates that the market views the issue price as highly attractive, given Corona Remedies' track record and future growth prospects in chronic therapy segments like urology and cardiology. For listing gain hunters, this is a strong signal to Apply.

Key Details You Need to Know

This IPO is a 100% Offer For Sale (OFS), meaning the entire issue size of ₹655.37 Cr will go to the selling promoters and shareholders. No funds will flow directly into the company’s balance sheet from the IPO.

The retail portion is reserved at 35%, offering good allotment prospects, especially for applications made at the upper price band of ₹1,062.

The Financial Engine: Why Corona Remedies is Growing Fast

The core reason behind the high Corona Remedies IPO GMP is the company's spectacular financial performance, particularly its rapid profitability growth over the last two years.

Financial Snapshot (₹ Crores)

Key Takeaways:

1. Profit Jump (65% Growth): Net Profit (PAT) skyrocketed from ₹90.50 Cr in FY2024 to an impressive ₹149.43 Cr in FY2025. This dramatic jump in profitability validates the success of their specialized marketing and product portfolio.

2. High Margins: The EBITDA margin has consistently improved, crossing the 20% mark in FY2025, a strong indicator of operational efficiency in the pharma space.

3. Near-Zero Debt: With a Debt-to-Equity ratio of just 0.10, the company is virtually debt-free. This robust balance sheet drastically reduces risk and provides immense stability, making it highly attractive to institutional investors.

Valuation: Fair Price for High Growth

Evaluating the price is key. Based on the upper price band of ₹1,062 and the strong FY2025 EPS of ₹24.43, the IPO is valued at a P/E multiple of 43.47x.

Is this expensive? Let's compare it to established industry peers:

Corona Remedies is priced on par or slightly below many of its larger, listed counterparts, despite being one of the fastest-growing in the top 30 Indian pharma companies. Given its superior growth rate and impressive profitability ratios (ROE 27.50%, ROCE 41.32%), the valuation is justified and appears attractive for long-term investors.

The Verdict: Apply for Listing Gains and Long Term

Corona Remedies is a fundamentally strong company utilizing its pan-India network of 2,671 medical agents to focus on high-margin chronic and specialty treatments. This strategy has delivered exceptional financial results.

• For Listing Gains: The robust Corona Remedies IPO GMP (30%+ potential gain) makes this a must-apply IPO for investors seeking quick returns.

• For Long-Term Holding: The company's exceptional growth, near-zero debt, and focus on stable therapeutic areas (urology, women's health, cardiometabolic) make it a strong candidate for wealth creation. While it's an OFS, the underlying company's health is top-tier.

Our Recommendation: APPLY for both listing gains and long-term investment.

Quick Fire FAQs

Q1. What is the latest Corona Remedies IPO GMP?

A: The latest Corona Remedies IPO GMP is estimated between ₹307 and ₹365 per share, indicating a potential listing gain of up to 34%.

Q2. When does the IPO open?

A: The subscription window opens on Monday, December 8, 2025, and closes on December 10, 2025.

Q3. Is this a Fresh Issue or OFS?

A: This is a 100% Offer For Sale (OFS). The IPO proceeds will go to the selling shareholders, not to the company's accounts.

Q4. Is the company highly leveraged?

A: No, the company has a very low Debt-to-Equity ratio of 0.10, making it one of the safest bets in terms of capital structure.